|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Products | |||||
| Products | |||||
| Milestone Arrangement | |||||
| Milestone and engineering | |||||
| Total products | |||||
| Costs and Expenses | |||||
| Costs of revenue | |||||
| Research, development and manufacturing operations | |||||
| Selling, general and administrative | |||||
| Share-based compensation | |||||
| Depreciation and amortization | |||||
| Total Costs and Expenses | |||||
| Loss from Operations | |||||
| Other Income/(Expense) | |||||
| Other income/(expense), net | |||||
| Warrant settlement (Note 10) | |||||
| Interest expense | |||||
| Total Other Income/(Expense) | |||||
| Income/(Loss) on Equity Method Investment | |||||
| Net Income/(Loss) | |||||
| Less: Series 1C preferred stock dividends | |||||
| Less: Down round deemed dividend | |||||
| Net Income Available to Common Shareholders | |||||
| Net Income/(Loss) Per Share (Basic) | |||||
| Net Income/(Loss) Per Share (Diluted) | |||||
| Weighted Average Common Shares Outstanding (Basic) | |||||
| Weighted Average Common Shares Outstanding (Diluted) | |||||
| Other Comprehensive Income/(Loss) | |||||
| Foreign currency translation gain/(loss) | |||||
| Net Comprehensive Income/(Loss) | |||||
Loading...